A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Prior treatment

• Prior history of allogeneic cell transplant.
• Received chemotherapy within 14 days prior to entering the study.
• Received biologic (\< 28 days), small molecule targeted therapies (\< 5 half-life) or other anti-cancer therapy within 21 days of study entry.
• Concurrent treatment with an investigational agent, 14 days for small molecular agents and/or 28 days for biologics treatment prior to the first dose of therapy.
• Radiation within 14 days of study entry, thoracic radiation within 28 days of study entry.
• Continuance of toxicities due to prior radiotherapy or chemotherapy agents that do not recover to ≤ Grade 1 except alopecia or neuropathy.
• Failure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients with active wound healing, patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry.
• Uncontrolled concurrent illness including, but not limited to: symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements.
• The last treatment for the subject before signing the informed consent was bcl-2 targeted drug treatment (if the subject had received bcl-2 inhibitor treatment but did not develop drug resistance, it could be included in this study).
• History of secondary active malignancies within the past 2 years. However, adequately treated superficial skin cancer other than melanoma, in-situ cervix cancer more than 4 weeks, or prostate cancer not requiring any treatment and under surveillance prior to enrollment will not be considered exclusionary.

Other illness

• Has gastrointestinal conditions that could affect the absorption of APG-2575 in the opinion of the Investigator.
• Unstable angina, myocardial infarction, or a coronary revascularization procedure within 180 days of study entry.
• Active rheumatoid arthritis (RA), active inflammatory bowel disease, or any other disease or condition associated with chronic inflammation.
• Active infection requiring systemic antibiotic/ antifungal medication, known clinically active hepatitis B or C infection, or known HIV disease.
• Known or suspected Wilson's Disease, or other conditions that affect copper accumulation or regulation.
• Known to be allergic to study drug ingredients or their analogues.
• Any other condition or circumstance that would, in the opinion of the investigator, make the patient unsuitable for participation in the study.

Other

• Patients who meet any of the following exclusion criteria are not to be enrolled in this study:
• Subjects have been diagnosed with Burkitt's lymphoma, Burkitt-like lymphoma, or lymphoblastic lymphoma/leukemia.
• Has known active central nervous system (CNS) involvement.
• Pregnancy or lactation, or pregnancy is expected during the study period or within 3 months after the last administration of APG-2575.

• Age ≥18 years old.
• Histologically confirmed diagnosis of chronic lymphocytic leukemia, or non-Hodgkin's lymphoma such as mantle cell lymphoma, diffuse large B cell lymphoma, Waldenstrom macroglobulinemia (WM).
• Patient must have relapsed or refractory to, intolerant to, or are considered ineligible for therapies known to provide clinical benefit.
• Life expectancy ≥ 3 months.
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 -1 in dose escalation; 0-2 in dose expansion.
• Corrected QT interval ≤450ms in males, and ≤470ms in females.
• Adequate bone marrow function independent of growth factor:
  • Absolute neutrophil count (ANC) ≥1.0 X 10E9/L.
  • Hemoglobin ≥ 8.0 g/dL.
  • Platelets count ≥ 30 X 10E9/L (entry platelet count must be independent of transfusion within 7 days of first dose).
• Adequate renal and liver function as indicated by:
  • Serum creatinine ≤ 1.5 x upper limit of normal (ULN); if serum creatinine is \>1.5 X ULN, creatinine clearance must be ≥60 mL/min.
  • Total bilirubin ≤1.5 x ULN, except subject with known Gilbert's syndrome.
  • Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) \<2.5 x ULN.
  • Alkaline phosphatase \< 2.5 x ULN and \< 5 x for bone metastases \&/or no hepatic parenchymal metastases on screening radiographic examination.
  • Thromboplastin time (aPTT)≤1.5 X ULN unless the subject is receiving anticoagulant therapy as long as prothrombin time (PT) or aPTT is within therapeutic range of intended use of anticoagulants.
• Willingness by both males, and female patients of child bearing potential, to use contraception by a method that is deemed effective by the investigator, throughout the treatment period and for at least three months following the last dose of study drug Postmenopausal women must be amenorrheal for at least 12 months to be considered of non-childbearing potential. All partners must have the same willingness for contraception methods throughout the treatment period and for at least three months following the last dose of study drug as well.
• Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the patient prior to any study-specific procedures).
• Willingness and ability to comply with study procedures and follow-up examination.